Tesamorelin

Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH) supplied in lyophilized form for reconstitution. It belongs to the growth hormone secretagogue class and is catalogued here under Weight Loss & Metabolic for laboratory research and professional reference purposes. This product is not approved by the FDA for therapeutic use and is provided strictly for research and professional use by licensed practitioners.

Within the research literature, Tesamorelin is of interest as a stabilized GHRH-receptor agonist studied to probe the somatotropic axis and downstream metabolic signaling. It is described as a tool compound for examining endogenous growth hormone secretion patterns rather than as a finished therapeutic agent. Where effects are referenced, individual results vary, and any application is at the sole discretion of the ordering licensed provider.

• Investigated in research literature for its reported relationship to regional and visceral adipose tissue distribution; individual results vary
• Studied as a probe of the GHRH-growth hormone-IGF-1 axis and pulsatile growth hormone secretion
• Reported in research settings in connection with lipid and broader metabolic parameters; individual results vary
• Investigated as a reference GHRH-receptor agonist for comparative secretagogue studies
• Explored in the literature in connection with body-composition and metabolic-marker research endpoints; individual results vary

Supplied as a lyophilized powder for laboratory handling. General reference practice described in the peptide-handling literature is to reconstitute with bacteriostatic water or another suitable sterile diluent by directing the diluent gently against the vial wall rather than directly onto the powder, then swirling without vigorous shaking until dissolved. Unreconstituted lyophilized vials are commonly stored refrigerated and protected from light and moisture; once reconstituted, the solution is generally kept refrigerated, protected from light, and used within a limited window per standard peptide-handling guidance. Repeated freeze-thaw cycles are generally avoided, and solution that appears cloudy or contains particulates is generally discarded. This information is provided as a storage and handling reference only; all clinical protocols, including any reconstitution ratios, dosing, and administration decisions, are determined solely by the licensed ordering provider, and this is reference information, not medical advice.

A per-lot Certificate of Analysis, HPLC purity profile, and mass-spectrometry verification are available on request for this product. Ask your account manager for the current lot documentation.

Tesamorelin is described in the research literature as a synthetic analog of human growth hormone-releasing hormone (GHRH) that is reported to bind and activate GHRH receptors on anterior pituitary somatotroph cells. Structural modification is reported to confer greater stability against enzymatic degradation relative to native GHRH, and receptor engagement is proposed to influence the synthesis and pulsatile release of endogenous growth hormone, with corresponding downstream effects described for IGF-1 signaling. Metabolic observations reported in research contexts are studied as possible consequences of this somatotropic activity; proposed mechanisms remain the subject of ongoing investigation and individual results vary.